Evidence map›Paper›PMID 27043038›Full record

ReviewExpert review of molecular diagnostics2016

Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?

Michael Boyiadzis, Theresa L Whiteside

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of molecular diagnostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. The theragnostic advances of exosomes in managing leukaemia.Journal of cellular and molecular medicine · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Noncoding RNome as Enabling Biomarkers for Precision Health.International journal of molecular sciences · 2022
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michael Boyiadzisa Department of Medicine, Division of Hematology-Oncology , University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.
Theresa L Whitesideb Department of Pathology , University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.
UPMC Hillman Cancer Center · US

Funding

Restoring anti-tumor immunity in the microenvironment of head and neck cancerR01CA168628 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHITESIDE, THERESA L. · 2013 to 2017
$1.7M
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapyR21CA205644 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BOYIADZIS, MICHAEL, WHITESIDE, THERESA L. · 2016 to 2017
$370k
NCI NIH HHS R01 CA168628NCI NIH HHS R21 CA205644
6 · The paper itself

Abstract

The recent emergence of plasma-derived exosomes as biomarkers of leukemic relapse has introduced the potential for more sensitive non-invasive monitoring of leukemia patients based on the molecular and genetic analysis of the exosome cargo. In principle, the protein, lipid, miRNA, mRNA or DNA profiles of exosomes in patients' plasma that associate with leukemic relapse can be identified. The diagnostic/prognostic value of these profiles could then be validated in prospective clinical studies. Here, we consider the potential of exosomes to fulfill the role of future biomarkers of minimal residual disease in AML. The rationale for developing exosome-based methodology for minimal residual disease detection is based on promising early observations. However, standards need to be established for evaluating exosome identity, isolation from body fluids, and assessment methods. The rapidly expanding knowledge of the exosome biology suggests that the exosome status as potential biomarkers may become clarified in the near future.

Indexed as

Biomarkers, TumorExosomesHumansLeukemia, Myeloid, AcuteMolecular Diagnostic TechniquesBiomarkers, Tumoracute myeloid leukemiabiomarkerExosomesleukemia relapseminimal residual disease

Identifiers

PMID27043038
PMCPMC5400097
OpenAlexW2342282460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.